Los Angeles Capital Management
RNAC icon

Los Angeles Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Los Angeles Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,632
Closed -$245K – 1440
2022
Q1 		$245K Sell
6,632
-422
-6% -$26.4K ﹤0.01% 1311
2021
Q4 		$690K Buy
7,054
+6,433
+1,036% +$692K ﹤0.01% 865
2021
Q3 		$78K Buy
621
+262
+73% +$31.6K ﹤0.01% 1456
2021
Q2 		$45K Buy
+359
New +$42.8K ﹤0.01% 1517

Other funds holding RNAC

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Los Angeles Capital Management's RNAC Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2022, closing a stake of 6,632 shares — an estimated $245K sold.

Los Angeles Capital Management first reported a position in RNAC in Q2 2021 and held it in 4 quarters. The position peaked at $690K in Q4 2021. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2022.

  • Los Angeles Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 6,632 Cartesian Therapeutics shares in Q2 2022, an estimated $245K.
  • Los Angeles Capital Management first reported a position in Cartesian Therapeutics in Q2 2021 and held it in 4 quarters.
  • Los Angeles Capital Management's Cartesian Therapeutics position peaked at $690K in Q4 2021.
  • 92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.